SCHEMBL483697

SCHEMBL483697

N#Cc1ccccc1CO

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
SMN1; SMN2 Q16637 3/20 0.49
MAPT P10636 1/20 0.49
CYP19A1 P11511 1/20 0.46
ESR2 Q92731 1/20 0.45
TSHR P16473 4/20 0.44
GALR3 O60755 1/20 0.43
RAB9A P51151 1/20 0.43
APOBEC3G Q9HC16 1/20 0.43
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
FFAR1 O14842 2/20 0.41
NOX4 Q9NPH5 1/20 0.40
LMNA P02545 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30496165 1.00 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2MAPTCYP19A1ESR2
Fluoride SCHEMBL27645948 0.98 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTCYP19A1ESR2
Bromide SCHEMBL4736034 0.98 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MAPTCYP19A1ESR2
SCHEMBL7667378 0.83 ESR2 (0.53) ALDH1A1SMN1; SMN2MAPTCYP19A1ESR2
SCHEMBL536176 0.82 FFAR1 (0.44) ALDH1A1SMN1; SMN2MAPTCYP19A1ESR2
SCHEMBL30129807 0.82 FFAR1 (0.44) ALDH1A1SMN1; SMN2MAPTCYP19A1ESR2
SCHEMBL1378624 0.80 CA1 (0.41) ALDH1A1SMN1; SMN2MAPTCYP19A1ESR2
SCHEMBL28215006 0.80 S1PR1 (0.40) ALDH1A1SMN1; SMN2MAPTCYP19A1ESR2
SCHEMBL2154210 0.80 SMN1; SMN2 (0.49) ALDH1A1SMN1; SMN2MAPTCYP19A1TSHR
SCHEMBL2153612 0.80 CYP19A1 (0.48) ALDH1A1SMN1; SMN2MAPTCYP19A1ESR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 371 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115572278-B Genipin derivative and preparation method and application thereof 北京志道生物科技有限公司 2023-09-01 CN claimed
CN-113816964-B Reversible ionic liquid for capturing carbon dioxide and synthesis method thereof 中国科学院兰州化学物理研究所 2023-02-10 CN claimed
CN-115572278-A Genipin derivative and preparation method and application thereof 北京志道生物科技有限公司 2023-01-06 CN claimed
WO-2022151968-A1 METHOD FOR PURIFYING KEY INTERMEDIATES OF CITALOPRAM 浙江华海药业股份有限公司 2022-07-21 WO claimed
CN-114488446-A Optical cable cladding capable of being repeatedly used and preparation method thereof 胡从美 2022-05-13 CN claimed
EP-3541791-A1 PROCESS FOR PRODUCTION OF AROMATIC COMPOUNDS COMPRISING AT LEAST TWO AMINE FUNCTIONS Rhodia Operations (FR) 2019-09-25 EP claimed
EP-2978852-B1 PRODUCTION OF PYRIPYROPENES FROM DRY BIOMASS BASF SE (DE) 2018-10-17 EP claimed
WO-2018085957-A1 PROCESS FOR PRODUCTION OF AROMATIC COMPOUNDS COMPRISING AT LEAST TWO AMINE FUNCTIONS RHODIA OPERATIONS (FR) 2018-05-17 WO claimed
WO-2018086491-A1 PROCESS FOR PRODUCTION OF AROMATIC COMPOUNDS COMPRISING AT LEAST TWO AMINE FUNCTIONS RHODIA OPERATIONS (FR) 2018-05-17 WO claimed
US-20140221631-A1 BORON-CONTAINING SMALL MOLECULES ANACOR PHARMACEUTICALS, INC. (US) 2014-08-07 US claimed
US-20040259940-A1 Process for the preparation of racemic citalopram and/or s-or r-citalopram by separation of a mixture of r-and s-citalopram H. LUNDBECK A/S (DK) 2004-12-23 US claimed
EP-1412341-B1 PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND/OR S- OR R-CITALOPRAM BY SEPARATION OF A MIXTURE OF R- AND S-CITALOPRAM LUNDBECK & CO AS H (DK) 2004-12-08 EP claimed
JP-2004536093-A 2004-12-02 JP claimed
EP-1412341-A1 PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND/OR S- OR R-CITALOPRAM BY SEPARATION OF A MIXTURE OF R- AND S-CITALOPRAM H. Lundbeck A/S (DK) 2004-04-28 EP claimed
US-6576372-B1 Hydroxy-containing substituent having a dipole moment is coupled to polyurethane through a NHCOO linkage NISSHINBO INDUSTRIES, INC. (JP) 2003-06-10 US claimed
WO-2003000672-A1 PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND/OR S- OR R-CITALOPRAM BY SEPARATION OF A MIXTURE OF R- AND S-CITALOPRAM H. LUNDBECK A/S (DK) 2003-01-03 WO claimed
EP-0132392-B1 ASYMMETRIC SYNTHESIS OF ALPHA-SUBSTITUTED-ALPHA-CYANOMETHYL ALCOHOLS ICI AUSTRALIA LIMITED (AU) 1992-01-02 EP claimed
US-4985365-A WITH AN ESTERASE FROM A MICROORGANISM, ASSYMETRIC HYDROLYSIS SUMITOMO CHEMICAL COMPANY, LTD. (JP) 1991-01-15 US claimed
EP-0347066-A1 New enantiomers and their isolation H. LUNDBECK A/S (DK) 1989-12-20 EP claimed
EP-0132392-A2 Asymmetric synthesis of alpha-substituted-alpha-cyanomethyl alcohols ICI AUSTRALIA LIMITED (AU) 1985-01-30 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221631-A1 BORON-CONTAINING SMALL MOLECULES ETF1, POLR1C, DPM1 ALDH1A1 3692/4885SMN1; SMN2 4595/4885MAPT 1768/4885
US-20040259940-A1 Process for the preparation of racemic citalopram and/or s-or r-citalopram by separation of a mixture of r-and s-citalopram SLC6A4, SRR, SLC6A2 ALDH1A1 1102/4885SMN1; SMN2 1432/4885MAPT 186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.